MOUNTAIN VIEW, Calif., March 31, 2015 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions for healthcare institutions, today announced the conclusion of an investigation into certain whistleblower allegations that had postponed the filing of its 2014 Annual Report on Form 10-K, and also announced that the 2014 report has now been filed with the Securities Exchange Commission. The whistleblower claim was received on February 27, 2015 and alleged, among other claims, the existence of a side letter arrangement with a customer that provided for discounts which were not recorded in the financial results of the Company.
After a thorough investigation, Omnicell concluded that a letter was written by a Company sales representative in 2010 to a single customer that summarized terms of a quotation and was presented to the customer in the normal course of the sales process. The Company concluded that the letter did not promise discounts to the customer that were not included in the Company's financial statements. Upon review of documents and other information related to this allegation and other sales activity at the Company, the Company reaffirmed that financial controls were operating effectively.
Omnicell takes all allegations of impropriety seriously and apologizes for any inconvenience caused by the delay of filing its Annual Report while this matter was investigated.
For more information about Omnicell, Inc. please visit www.omnicell.com.
Logo - http://photos.prnewswire.com/prnh/20120731/SF48971LOGO-a
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/omnicell-inc-announces-conclusion-of-whistleblower-investigation-and-filing-of-2014-annual-report-on-form-10-k-300058100.html
SOURCE Omnicell, Inc.